Shattuck Labs, Inc. Operating Lease Right-of-Use Assets
Shattuck Labs, Inc. (STTK) had Operating Lease Right-of-Use Assets of $1.34 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-03-05
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.34M.
- 2024-12-31: Operating Lease, Right-of-Use Asset $1.84M.
- 2023-12-31: Operating Lease, Right-of-Use Asset $2.27M.
- 2022-12-31: Operating Lease, Right-of-Use Asset $2.63M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2025-12-31 | $1.34M 10-K · filed 2026-03-05 |
| 2024-12-31 | $1.84M 10-K · filed 2026-03-05 |
| 2023-12-31 | $2.27M 10-K · filed 2025-03-27 |
| 2022-12-31 | $2.63M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.72M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $2.80M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.87M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |